RVL Pharmaceuticals plc financial data

Symbol
RVLPQ on OTC
Industry
Pharmaceutical Preparations
Location
400 Crossing Boulevard, Bridgewater, New Jersey
State of incorporation
Ireland
Fiscal year end
December 31
Former names
Osmotica Pharmaceuticals plc (to 1/18/2022), Osmotica Pharmaceuticals Ltd (to 8/22/2018)
Latest financial report
10-Q - Q2 2023 - Aug 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % -4.81%
Quick Ratio 2.36 % -11.3%
Debt-to-equity 173 % +70.1%
Return On Equity -155 % -78.1%
Return On Assets -56.8 % -31.6%
Operating Margin -192 % +4.05%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.5M shares +0.39%
Common Stock, Shares, Outstanding 99.4M shares +18.9%
Entity Public Float 44.9M USD -27%
Common Stock, Value, Issued 994K USD +18.9%
Weighted Average Number of Shares Outstanding, Basic 99.4M shares +18.9%
Weighted Average Number of Shares Outstanding, Diluted 99.4M shares +18.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 36.9M USD +5.64%
Research and Development Expense 3.1M USD -34.2%
Operating Income (Loss) -70.8M USD -1.36%
Nonoperating Income (Expense) 6.95M USD +39.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -68.5M USD -4.47%
Net Income (Loss) Attributable to Parent -68.3M USD -20.8%
Earnings Per Share, Basic -0.72 USD/shares +4%
Earnings Per Share, Diluted -0.72 USD/shares +4%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 1M USD
Inventory, Net 1.36M USD +157%
Assets, Current 25.8M USD -35.9%
Operating Lease, Right-of-Use Asset 365K USD -58.1%
Intangible Assets, Net (Excluding Goodwill) 13.9M USD -48.9%
Goodwill 55.8M USD 0%
Assets 85.4M USD -31.6%
Accrued Liabilities, Current 7.86M USD -34.2%
Liabilities, Current 68.4M USD +269%
Contract with Customer, Liability, Noncurrent 1.2M USD +500%
Accrued Income Taxes, Noncurrent 71K USD +5.97%
Deferred Income Tax Liabilities, Net 25K USD -85.6%
Operating Lease, Liability, Noncurrent 180K USD -48.4%
Liabilities 69.1M USD +4.16%
Retained Earnings (Accumulated Deficit) -605M USD -12.7%
Stockholders' Equity Attributable to Parent 16.3M USD -72.1%
Liabilities and Equity 85.4M USD -31.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.82M USD +56.2%
Net Cash Provided by (Used in) Financing Activities -4.86M USD -481%
Net Cash Provided by (Used in) Investing Activities -1.23M USD -12350%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 99.4M shares +18.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.2M USD -30.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.54M USD +211%
Deferred Tax Assets, Valuation Allowance 64.9M USD +22.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure -85.5%
Operating Lease, Liability 529K USD -63%
Payments to Acquire Property, Plant, and Equipment 1.3M USD +4730%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -68.3M USD -25.8%
Lessee, Operating Lease, Liability, to be Paid 538K USD -63.6%
Operating Lease, Liability, Current 197K USD -64.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93K USD -81.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 445K USD -49.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure -24.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9K USD -81.3%
Deferred Tax Assets, Operating Loss Carryforwards 26.9M USD +27.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 179K USD +2.29%
Additional Paid in Capital 620M USD +4.36%
Preferred Stock, Shares Outstanding 0 shares
Current Federal Tax Expense (Benefit) 4.1M USD
Depreciation, Depletion and Amortization 93K USD +4.49%
Share-based Payment Arrangement, Expense 2.21M USD -68.4%
Interest Expense 1.19M USD -70.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%